PipelineReview.com5h
Vaxxas Licenses Next-Generation Vaccine for Respiratory Syncytial Virus (RSV) from the United States National Institutes of Health (NIH)
BRISBANE, Australia & CAMBRIDGE, MA, USA I8, 2024 I Vaxxas, a clinical-stage biotechnology company commercializing a novel ...
PipelineReview.com5h
Kivu Bioscience Raises $92 Million Series A Led by Novo Holdings to Advance Next-Generation Antibody-Drug Conjugates
SAN FRANCISCO, CA, USA I8, 2024 I Kivu Bioscience, a biotech company developing next-generation antibody-drug conjugates to deliver best-in-class ...
PipelineReview.com5h
IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors
SOUTH SAN FRANCISCO, CA, USA I8, 2024 I IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and ...
PipelineReview.com5h
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
Agreement expected to accelerate MRT-6160 clinical development and broadly explore therapeutic opportunities across multiple indications ...
PipelineReview.com5h
AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer’s Disease and Neuroscience Pipeline
NORTH CHICAGO, IL and BOSTON, MA, USA I8, 2024 I AbbVie (NYSE: ABBV) and Aliada Therapeutics today announced a definitive agreement under which ...
PipelineReview.com10h
Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
ORLYNVAH™ is the first oral penem approved for use in the U.S. and the second FDA-approved treatment for uUTIs in the past two decades ...
PipelineReview.com10h
Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis
New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral ...